Minimizing Long-Term Tumor Burden: The Logic for Metronomic Chemotherapeutic Dosing and its Antiangiogenic Basis
- 1 February 2003
- journal article
- Published by Elsevier in Journal of Theoretical Biology
- Vol. 220 (4) , 545-554
- https://doi.org/10.1006/jtbi.2003.3162
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Cancer: the evolved consequence of a destabilized genomeBioEssays, 2001
- Overview of angiogenesis: Biologic implications for antiangiogenic therapySeminars in Oncology, 2001
- Cancer: looking outside the genomeNature Reviews Molecular Cell Biology, 2000
- Chemotherapeutic drugs—more really is not betterNature Medicine, 2000
- The Linear-Quadratic Model and Most Other Common Radiobiological Models Result in Similar Predictions of Time-Dose RelationshipsRadiation Research, 1998
- Antiangiogenic therapy of experimental cancer does not induce acquired drug resistanceNature, 1997
- Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancerBritish Journal of Cancer, 1996
- Prediction of the maximal tolerated dose (MTD) and therapeutic effect of anticancer drugs in humans: integration of pharmacokinetics with pharmacodynamics and toxicodynamicsCancer Treatment Reviews, 1995
- Advances in Diagnostic Imaging and Overestimations of Disease Prevalence and the Benefits of TherapyNew England Journal of Medicine, 1993
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971